Evolution of the Average Target: UCB

Evolution of the Average Target - UCB

Evolution of the Target Price: UCB

Evolution of the Target Price - UCB

Changes in Analyst Recommendations: UCB

eee45ba0785574.zXAePbHgiDFfXc67QYvkrXT7GPU7dfEIK6RUpDjIwik.iSYmCYiUwQMzapmOB-XU_h-WdL9JA6hRbM8OwHCrllOoElJ_xbPbZww7iw~d20f8b4e3104e03ff2dd1216972c0188
11:00am FDA green light for UCB and positive view from DB Zonebourse
09-24 BofA Reaffirms UCB at Buy Amid 'Very Confident' Outlook for Psoriasis Drug MT
09-24 BofA Securities Keeps UCB at Buy MT
09-11 AlphaValue/Baader Europe Sees UCB Share Drop as 'Rare Window of Affordability'; Price Target Up MT
09-10 UCB: A rare window of affordability Alphavalue
08-20 Cancer vaccines finally garner the spotlight Alphavalue
08-18 UCB: An unimpressive upgrade-led correction opens a rare opportunity Alphavalue
08-11 Berenberg Adjusts UCB Forecasts After H1 Beat; Buy Reaffirmed MT
08-11 UCB barely moves despite positive calls from ING and Berenberg Zonebourse
07-31 AlphaValue/Baader Europe Upgrades UCB to Add, Trims PT MT
07-30 Kempen Upgrades UCB to Buy Rating, Boosts PT MT
07-14 Where would AI lead Pharma in the long run? Alphavalue
07-03 Berenberg Updates Price Target, Estimates for UCB on Recent Pipeline Deals MT
06-22 UBS Trims UCB's PT, Affirms Buy Rating MT
06-15 UCB Slumps Following Analyst Downgrade Zonebourse
06-15 Barclays Downgrades UCB to Equalweight, Trims PT MT
06-15 UCB Kept at Buy as BofA Notes Psoriasis Drug Momentum MT
06-09 UCB Favored by Oddo BHF Zonebourse
06-05 KBC Securities Maintains Buy Rating on UCB Zonebourse
05-21 UCB Price Target, Estimates Up as AlphaValue/Baader Europe Notes Growth Momentum MT
05-20 UCB: Executing well, but valuation lacks safety net Alphavalue
04-27 AlphaValue/Baader Europe Upgrades UCB to Reduce, Trims PT MT
03-30 MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says MT
03-16 Berenberg says Belgian drugmaker UCB stock is undervalued Zonebourse
03-16 Berenberg Keeps UCB Amid Positive Pipeline Progress, H2 Catalysts MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+38.35%
+6.11%
+10.32%
-0.28%
+9.26%
-0.65%
-1.09%
+24.17%
-9%
+1.57%
Average +7.88%
Weighted average by Cap. +5.52%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
206.00EUR
Average target price
285.00EUR
Spread / Average Target
+38.35%
High Price Target
340.00EUR
Spread / Highest target
+65.05%
Low Price Target
208.00EUR
Spread / Lowest Target
+0.97%

Analyst Consensus Detail

Analyst consensus - UCB

Consensus revision (last 18 months)

Consensus revision (last 18 months) - UCB
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - UCB